INTRODUCTION
============

Hysterectomy is the most common major gynecologic surgical procedure performed in the United States. Although there are more than 600000 hysterectomies performed annually, most of these procedures (\>65%) are performed through open laparotomy incisions and for benign indications. Overall, total laparoscopic hysterectomy represents only a small percentage of all hysterectomy procedures performed, despite the many benefits of this approach, including decreased postoperative pain and blood loss, shorter hospitalization and return to normal activity, fewer wound infections, and smaller reduction in hemoglobin levels.^[@B1]--[@B5]^

The poor adoption of the total laparoscopic hysterectomy procedure for benign conditions probably relates to several factors, including the steep learning curve and longer operative times of the procedure, as well as the development of the necessary laparoscopic suturing skills.^[@B4]--[@B10]^ Gynecologic surgeons have more recently adopted robotic-assisted hysterectomy as a way to mitigate some of the challenges associated with the total laparoscopic hysterectomy procedure while maintaining many benefits of the laparoscopic surgical approach. The da Vinci surgical system (Intuitive Surgical, Sunnyvale, CA, USA), the only Food and Drug Administration--approved robotic surgical platform for gynecologic surgery, offers an articulating wristed motion with 7 *df* that mimics many of the movements of the surgeon\'s hand, 3-dimensional stereoscopic visualization, and improved ergonomics. This may enable the surgeon to perform more natural laparoscopic suturing during vaginal cuff closure, which is often considered a rate-limiting step in developing the appropriate skills needed to perform the laparoscopic hysterectomy procedure.^[@B9]--[@B17]^

Despite these benefits, the cost of performing robotic-assisted hysterectomy procedures remains high, and such procedures may not result in any operating room time savings or overall improved outcomes.^[@B14]--[@B17]^ The Endo Stitch (ES) (Covidien, Mansfield, MA, USA) is a disposable automated laparoscopic suturing device that allows the surgeon to perform efficient laparoscopic suturing using traditional laparoscopic surgical technique, without the associated steep learning curve of using needle drivers for laparoscopic suturing or the need for robotic surgical assistance. This device has been shown to reduce laparoscopic suturing and knot-tying time.^[@B18]--[@B20]^ The following question is then raised: Can a disposable automated laparoscopic suturing device, by facilitating more efficient vaginal cuff closure, enable surgeons to perform more cost-effective total laparoscopic hysterectomy procedures for benign conditions? The goal of this study is to evaluate hospital cost and operating room time differences in the performance of an inpatient total laparoscopic hysterectomy procedure, by use of a large standardized multihospital database, to compare an ES-facilitated total laparoscopic hysterectomy for benign conditions and a total laparoscopic hysterectomy without the use of the device using traditional laparoscopic technique, as well as a robotic-assisted laparoscopic hysterectomy.

METHODS
=======

Data Source
-----------

The University of South Florida Institutional Review Board reviewed the study and determined that Institutional Review Board approval was not necessary to conduct this study. A retrospective study was conducted using data from the database maintained by Premier (Premier Perspective Database \[PPD\]; Premier, Charlotte, NC, USA) (2010). The PPD is one of the largest hospital-based, service-level comparative databases in the United States, providing detailed resource utilization data along with patients\' principal and secondary diagnoses and procedure codes. The PPD contains drug utilization data on \>150 million hospital-outpatient visits and \>45 million inpatient visits over the past 7-year period from \>400 hospitals. This equates to approximately 1 of every 5 inpatient discharges in the United States. The PPD provides a broad perspective of patient discharge data from a variety of health systems, including not-for-profit, nongovernmental, community, and teaching hospitals.

The Uniform Billing--92 discharge forms provide data on demographic characteristics, discharge diagnoses, and discharge status (including death, but not its cause). Patient records in the PPD used for this study were deidentified in compliance with the Health Insurance Portability and Accountability Act of 1996. Each record in the PPD documents a single hospital discharge episode. The discharge record includes medical and surgical procedure codes (*International Classification of Diseases, Ninth Revision, Clinical Modification* \[ICD-9-CM\] procedure codes), hospital length of stay, and hospitalization cost. In the PPD costs are defined as the actual cost to treat the patient, which includes all supplies, labor, and depreciation of equipment. These costs include both fixed costs, which do not vary based on the volume of procedures performed, and variable costs, which are the direct costs and may vary based on the volume of procedures performed, hospital census, and average wholesale price. Hospitalization costs include, but are not limited to, costs associated with room and board (including the intensive care unit), surgery (including operating room costs), central supplies (including all medical devices and disposables such as staplers, sutures, and ES refills), anesthesia, laboratory, pharmacy, emergency department, pathology, blood bank, and ultrasonography. The cost of a device, such as an ES and its reloads, are included in central supplies. All direct hospital costs are reported, with the exception of the acquisition or maintenance costs of the da Vinci surgical system.

Study Population
----------------

All inpatient discharges with a primary procedure for a total laparoscopic hysterectomy (ICD-9-CM procedure code 68.41) between January 1, 2009, and June 30, 2011, were selected. Detailed billing data were used to search for the use of ES and robotic procedures. Patients were further categorized into 3 groups: (1) those for whom ES was used during the procedure, (2) those for whom robotic assistance (RA) was used, and (3) those for whom neither ES nor RA (NER) was used. In addition to billing data, ICD-9-CM procedure code 17.42 (laparoscopic robotic-assisted procedures) was used to identify robotic-assisted surgery discharges. All patients with a primary diagnosis of cervical, uterine, ovarian, or tubal cancers were excluded because the performance of a laparoscopic hysterectomy in these patients is typically more complicated and time-consuming, these procedures are generally performed by subspecialist gynecologic oncologists, and these procedures are not reflective of most benign laparoscopic hysterectomy procedures performed in the United States.

Adjustment for Comorbid Conditions and Severity of Illness
----------------------------------------------------------

The Charlson Comorbidity Index was used to identify comorbid conditions.^[@B21]^ The Charlson Comorbidity Index was developed in 1987 and was based on 1-year mortality data from a New York hospital. Nineteen comorbidities were identified with this method (myocardial infarction, diabetes, etc.).

All Patient--Refined Diagnosis-Related Groups are a joint development of 3M Health Information Systems (3M™ Health Information Systems, Salt Lake City, UT) and the National Association of Children\'s Hospitals and Related Institutions. The All Patient--Refined Diagnosis-Related Groups expand the basic diagnosis-related group structure by adding 4 subclasses to each diagnosis-related group. The addition of 4 subclasses addresses patient differences related to severity of illness and risk of death. The severity of illness and risk of death relate to distinct patient attributes. The 4 severity-of-illness subclasses and the 4 risk-of-death subclasses are numbered sequentially from 1 to 4, indicating minor, moderate, major, and extreme severity of illness, respectively.^[@B22]^

Statistical Analysis
--------------------

Descriptive statistics were calculated for patient demographic and hospital characteristics. Comparison of patient demographic and hospital characteristics was performed with 2-sided χ^2^ tests for categorical variables and *t* tests for continuous variables. Multivariate analysis was performed to examine the association among the ES, RA, and NER groups with respect to hospital cost, length of stay, and surgery time. Hospital cost data were transformed by taking the natural log of the cost values to reduce the effects of skewed distribution. Generalized estimating equation models with gamma distribution and log-link function were used to measure the impact of the technique used on the outcomes. Generalized estimating equation models represent an alternative generalization of generalized linear models that is often used to analyze correlated data. For patients treated in the same hospital, the overall cost and clinical outcomes are often correlated. The multivariate analysis controlled for the patient\'s age, race, severity of illness, and comorbid conditions, as well as hospital characteristics, such as bed size, region, and teaching status. Comorbid conditions included chronic obstructive pulmonary disease, diabetes, hypertension, and obesity. The analysis included clustering of patients receiving care from the same hospital. Statistical significance was evaluated at α = .05. All analyses were performed with SAS software, version 9.1 (SAS Institute, Cary, NC, USA).

RESULTS
=======

A total of 11133 patients with a primary procedure of an inpatient total laparoscopic hysterectomy between January 1, 2009, and June 30, 2011, were identified. All patients with a primary diagnosis of cervical, uterine, ovarian, or tubal cancers were excluded (n = 1825, 16.4%). Of the remaining 9308 patients, the ES was used in 974 (10%), RA was used in 3971 (43%), and neither technique was used in 4363 (47%) (**[Figure 1](#F1){ref-type="fig"}**). Patients in the ES group were approximately 1.5 years younger than those in the RA and NER groups (**[Table 1](#T1){ref-type="table"}**). There were significantly more Hispanics in the ES group compared with the other 2 groups (*P* \< .001). There was no difference in severity of illness among the 3 groups. Similarly, there were no differences in the number of patients with chronic pulmonary disease, diabetes, or non-obstetric/gynecologic cancers among the 3 groups. However, patients in the RA and NER groups had a higher rate of hypertension and obesity compared with the ES group. Teaching hospitals were more likely to use RA compared with the other 2 groups (*P* \< .001).
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###### 

Demographic Characteristics, Comorbid Conditions, and Hospital Characteristics for Patients With Use of ES, Use of RA, and Use of Neither Technique

                                           ES (n = 974), n (%)   RA (n = 3971), n (%)   *P* Value[\*](#TF1-1){ref-type="table-fn"}   NER, n (%)    *P* Value[†](#TF1-2){ref-type="table-fn"}
  ---------------------------------------- --------------------- ---------------------- -------------------------------------------- ------------- -------------------------------------------
  Demographic characteristics                                                                                                                      
      Age, mean ± SD, y                    44.3 ± 10             45.8 ± 11              \<.001                                       45.7 ± 10     .0004
      Race                                                                                                                                         
          White                            619 (63.6)            2909 (73.3)            \<.001                                       2979 (68.3)   .0044
          African American                 127 (13.0)            469 (11.8)             .2913                                        568 (13.0)    .9863
          Hispanic                         91 (9.3)              201 (5.1)              \<.001                                       192 (4.4)     \<.001
          Other                            137 (14.1)            392 (9.9)              .0001                                        624 (14.3)    .8487
      APR-DRG severity of illness                                                                                                                  
          Mild                             715 (73.4)            2827 (71.2)            .1689                                        3136 (71.9)   .335
          Moderate                         232 (23.8)            1051 (26.5)            .0912                                        1107 (25.4)   .312
          Severe                           23 (2.4)              83 (2.1)               .6004                                        107 (2.5)     .8676
          Extreme                          4 (0.4)               8 (0.2)                .2344                                        13 (0.3)      .5724
      Comorbid conditions                                                                                                                          
          Chronic pulmonary disease        107 (11)              425 (10.7)             .7984                                        435 (10.0)    .3428
          Diabetes                         52 (5.3)              296 (7.5)              .0207                                        306 (7.0)     .0589
          Non-gynecologic primary cancer   24 (2.5)              88 (2.2)               .6411                                        73 (1.7)      .0948
          Hypertension                     198 (20.3)            987 (24.9)             .003                                         1062 (24.3)   .0077
          Obesity                          103 (10.6)            582 (14.7)             .001                                         556 (12.7)    .0629
  Provider characteristics                                                                                                                         
      Region                                                                                                                                       
          South                            476 (48.9)            1308 (32.9)            \<.001                                       1723 (39.5)   \<.001
          Northeast                        179 (18.4)            664 (16.7)             .2179                                        885 (20.3)    .1782
          Midwest                          166 (17.0)            1301 (32.8)            \<.001                                       1071 (24.6)   \<.001
          West                             153 (15.7)            698 (17.6)             .1661                                        684 (15.7)    .9807
  Hospital characteristics                                                                                                                         
      Teaching hospital                    268 (27.5)            1423 (35.8)            \<.001                                       1642 (37.6)   \<.001
      Urban                                956 (98.2)            3104 (78.2)            \<.001                                       3970 (91.0)   \<.001
      Hospital bed size                                                                                                                            
          \<250                            176 (18.1)            626 (15.8)             .0803                                        930 (21.3)    .038
          250--500                         366 (37.6)            2008 (50.6)            \<.001                                       2369 (54.3)   \<.001
          \>500                            432 (44.4)            1337 (33.7)            \<.001                                       1064 (24.4)   \<.001

For the ES and RA groups, the *P* value is based on χ^2^ and *t* tests for categorical and continuous variables, respectively.

For the ES and NER groups, the *P* value is based on χ^2^ and *t* tests for categorical and continuous variables, respectively.

APR-DRG = All Patient--Refined Diagnosis-Related Group.

**[Tables 2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}** show the unadjusted differences in total hospital costs, departmental costs, length of stay, and surgery time for the ES group versus RA group and the ES group versus NER group, respectively. The use of RA for the laparoscopic hysterectomy procedure was associated with a higher mean hospitalization cost compared with the use of the ES alone, a difference of \$1287 (*P* \< .001). This higher cost was mostly because of a higher surgery cost (\$2760 vs \$3585, *P* \< .001). The mean surgery time was significantly shorter for the ES group compared with the RA group, a difference of 41 minutes (*P* \< .001). The use of the ES was also associated with a lower mean hospitalization cost compared with the NER group, a difference of \$655 (*P* \< .001). This lower cost was mostly attributed to lower surgery cost (\$2760 vs \$3435, *P* \< .001). The mean surgery time was significantly shorter for patients in whom the ES was used compared with the NER group, a difference of 29 minutes (*P* \< .001).

###### 

Unadjusted Hospital Cost, Departmental Cost, Length of Stay, Surgery Time, and Cost Between ES and RA Groups

                               ES (n = 974)   RA (n = 3971)    Difference   *P* Value                 
  ---------------------------- -------------- ---------------- ------------ ---------------- -------- --------
  Hospitalization cost, \$     8073           7852, 8295       9360         9216, 9504       −1287    \<.001
      Room and board           1266           1184, 1348       1106         1069, 1142       160      .0002
      Central supply           2249           2161, 2338       2718         2649, 2786       −469     \<.001
      Surgery                  2760           2656, 2864       3583         3502, 3664       −823     \<.001
      Anesthesia               574            537, 612         446          432, 460         129      \<.001
      Pharmacy                 379            356, 402         396          374, 419         −18      .2893
      Laboratory               90             82, 98           102          97, 108          −12      .0437
      Other                    896            837, 954         1231         1188, 1273       −335     \<.001
  Hospital length of stay, d   1.53           1.46, 1.60       1.40         1.36, 1.43       0.14     .0008
  Surgery time, min            163            157.90, 167.10   203.80       200.50, 207.00   −41.30   \<.001
  Surgery cost/min, \$         17             17, 18           17           16, 17           0.81     .0539

###### 

Unadjusted Hospital Cost, Departmental Cost, Length of Stay, Surgery Time, and Cost Between ES and NER Groups

                               ES (n = 974)   NER (n = 4363)   Difference   *P* Value            
  ---------------------------- -------------- ---------------- ------------ ------------ ------- --------
  Hospitalization cost, \$     8073           7852, 8295       8728         8556, 8900   −655    \<.001
      Room and board           1266           1184, 1348       1294         1223, 1365   −28     .6195
      Central supply           2249           2161, 2338       2133         2083, 2183   117     .0249
      Surgery                  2760           2656, 2864       3435         3360, 3511   −675    \<.001
      Anesthesia               574            537, 612         572          553, 592     2       .9138
      Pharmacy                 379            356, 402         398          371, 425     −19     .2966
      Laboratory               90             82, 98           113          106, 120     −23     \<.001
      Other                    896            837, 954         948          916, 981     −53     .1229
  Hospital length of stay, d   1.53           1.46, 1.60       1.54         1.49, 1.59   −0.01   .8798
  Surgery time, min            163            158, 167         191          189, 193     −29     \<.001
  Surgery cost/min, \$         17             17, 18           17           17, 18       0.27    .487

The results of the multivariate analysis, adjusted for confounders (including patient\'s age, race, severity of illness, and comorbid conditions and hospital teaching status, region, and bed size) are shown in **[Tables 4](#T4){ref-type="table"}** and **[5](#T5){ref-type="table"}**. The mean hospital cost remained significantly lower for the ES group compared with the RA group after we adjusted for confounding variables, with the difference increasing to \$1769 (*P* = .0332). Similar to the unadjusted results, most of the cost difference observed was because of a lower mean surgery cost in the ES group compared with the RA group: \$2572 compared with \$4120 (*P* = .0065). The mean surgery time remained significantly shorter for patients in the ES group compared with the RA group, a difference of 42 minutes (*P* \< .001).

###### 

Adjusted Hospital Cost, Departmental Cost, Length of Stay, Surgery Time, and Cost Between ES and RA Groups

                               ES (n = 974)   RA (n = 3971)   Difference   *P* Value             
  ---------------------------- -------------- --------------- ------------ ------------ -------- --------
  Hospitalization cost, \$     7859           6730, 9176      9628         9216, 9504   −1769    .0332
      Room and board           1271           1078, 1500      1091         1069, 1142   180      .0523
      Central supply           2333           1894, 2874      2686         2649, 2786   −352     .1934
      Surgery                  2572           1960, 3374      4120         3502, 3664   −1548    .0065
      Anesthesia               474            373, 603        481          432, 460     −7       .8299
      Pharmacy                 346            301, 398        354          374, 419     −8       .7129
      Laboratory               101            81, 126         110          173, 3       −10      .3363
      Other                    1126           912, 1392       1073         1188, 1273   53       .5237
  Hospital length of stay, d   1.48           1.37, 1.60      1.39         1.30, 1.43   0.10     .062
  Surgery time, min            176            154, 200        218          203, 234     −42.38   \<.001
  Surgery cost/min, \$         14             11, 16          17           15, 21       −3.91    .0015

###### 

Adjusted Hospital Cost, Departmental Cost, Length of Stay, Surgery Time, and Cost Between ES and NER Groups

                               ES (n = 974)   NER (n = 4363)   Difference   *P* Value            
  ---------------------------- -------------- ---------------- ------------ ------------ ------- -------
  Hospitalization cost, \$     8186           7475, 8966       8820         8282, 9394   −634    .0879
      Room and board           1256           1052, 1500       1270         1129, 1428   −13     .6195
      Central supply           2192           1928, 2493       1988         1795, 2202   205     .0511
      Surgery                  3142           2733, 3611       3745         3375, 4156   −603    .0225
      Anesthesia               522            448, 609         554          478, 643     −32     .1114
      Pharmacy                 328            282, 381         354          308, 407     −26     .2544
      Laboratory               92             75, 114          109          92, 128      −17     .0281
      Other                    917            778, 1081        939          820, 1076    −22     .6851
  Hospital length of stay, d   1.44           1.32, 1.57       1.48         1.38, 1.58   −0.04   .3611
  Surgery time, min            180            163, 199         201          192, 211     −21     .0103
  Surgery cost/min, \$         17             16, 19           19           17, 20       −1.45   .0131

The mean hospitalization cost for the ES group also remained lower in the adjusted data (though not significantly) compared with the NER group, a difference of \$634 (*P* \< .0879). The mean surgery cost for the ES group was significantly lower than that for the NER group, a difference of \$603 (*P* = .0225). The mean surgery time was also significantly shorter for the ES group compared with the NER group, a difference of 21 minutes (*P* = .0103).

DISCUSSION
==========

One of the significant limiting factors preventing more surgeons from shifting from an open abdominal hysterectomy to a total laparoscopic hysterectomy procedure is the ability to suture laparoscopically. Although both RA and the ES automated suturing device facilitate more efficient development of this skill set, this study suggests that a benign total laparoscopic hysterectomy performed with a disposable automated laparoscopic suturing device is significantly more cost-effective than when performed with the da Vinci surgical system or with traditional laparoscopic suturing technique. This is also consistent with the limited data available in the medical literature, which have shown that overall costs are reduced by use of traditional laparoscopic techniques, compared with RA, for the performance of a laparoscopic hysterectomy procedure.^[@B14]--[@B16]^ As cost containment takes on even greater importance in the US health care system, lower-cost alternatives to more expensive technologies will increasingly become necessary, and economic outcomes data will be used more often in appropriate surgical instrumentation use decision making.

Despite the many advantages of performing a total laparoscopic hysterectomy, as well as the increasing popularity of this procedure, most hysterectomies in the United States are still performed by the open abdominal route. This appears to be partially related to the steep learning curve of the total laparoscopic hysterectomy procedure, as well as the limited exposure of residents to this procedure during training.^[@B1]--[@B10]^ The da Vinci surgical system has several advantages over traditional laparoscopic instrumentation, including 3-dimensional visualization, 7-*df* wristed motion, and improved ergonomics. These advantages have been promoted as a way for gynecologic surgeons to reduce the steep learning curve of the total laparoscopic hysterectomy procedure, especially related to the development of laparoscopic suturing skills, which is essential for laparoscopic vaginal cuff closure and represents one of the most challenging aspects of this procedure.^[@B4],[@B9]--[@B17]^

These advantages of the da Vinci surgical system have led to a more rapid adoption of robotic-assisted hysterectomy procedures,^[@B23]^ although widespread use is still limited by cost, lack of haptic feedback, and insufficient clinical comparative data showing improved outcome over traditional laparoscopic hysterectomy procedures. A Cochrane Database Systematic Review in 2012 concluded that the limited evidence in the medical literature did not show the benefit of robotic surgery for women with benign gynecologic diseases, including hysterectomy, in terms of effectiveness or safety.^[@B16]^ Although this review only evaluated 2 randomized clinical trials consisting of 158 women, the authors concluded that the robotic-assisted approach to benign gynecologic procedures may increase postoperative complications and cost, may lengthen the operating time, and failed to show any superiority compared with laparoscopic surgery.

In 2010 Sarlos et al.^[@B15]^ performed a prospective matched case-control study of their first 40 consecutive robotic-assisted hysterectomies for benign conditions and matched these cases 1:1 with their laparoscopic hysterectomy cases. They found that the robotic hysterectomy procedure was feasible and safe with a quick learning curve and that surgical outcomes (complications, conversion to laparotomy, intraoperative bleeding, and hospital stay) were comparable. They also found that robotic-assisted hysterectomy procedures were associated with longer operating room times and higher costs compared with the matched laparoscopic hysterectomy cases. The mean operating room time was 109 minutes versus 82.9 minutes and the mean cost was €4067 versus €2151 in the robotic-assisted hysterectomy group versus the laparoscopic hysterectomy group. Most of the cost difference, €2217 versus €822, was in the material costs of the procedure.

Also in 2010, Pasic et al.^[@B14]^ examined data in the Premier hospital database on 36188 patients treated at 358 hospitals undergoing a laparoscopic hysterectomy in 2007 and 2008. In this study 1661 robotic-assisted hysterectomy procedures were compared with 34527 traditional laparoscopic hysterectomy procedures. The authors found that both inpatient and outpatient robotic-assisted hysterectomy procedural costs and surgical times were significantly higher than those of laparoscopic hysterectomy procedures, without any difference in adverse events. Inpatient robotic-assisted hysterectomy procedures were approximately \$2600 more expensive and 0.4 hours longer and outpatient robotic-assisted hysterectomy procedures were approximately \$1900 more expensive and 0.5 hours longer than a laparoscopic hysterectomy procedure.

In our study the cost of performing a robotic-assisted hysterectomy was significantly greater than the cost of performing an ES-assisted total laparoscopic hysterectomy after we adjusted for confounders (including patients\' age, race, severity of illness, and comorbid conditions, as well as hospital teaching status, region, and bed size). The hospital cost of a robotic-assisted laparoscopic hysterectomy (\$9628), as compared with the ES-assisted total laparoscopic hysterectomy (\$7859), showed a cost difference of \$1769 per surgical case. Most of the additional hospital cost differences between these 2 techniques were related to the cost of surgery (\$1548 difference) and longer operating times (42-minute difference), making the robotic-assisted hysterectomy procedure substantially more expensive and time-consuming. Even with the additional cost of the ES device to facilitate laparoscopic suturing during a total laparoscopic hysterectomy procedure, it was still more cost-effective compared with performing a traditional laparoscopic hysterectomy procedure without the device, resulting in a \$634 cost savings and 21-minute time savings.

The data in this study only examined costs directly related to hospitalization and did not take into account the acquisition and maintenance costs of the da Vinci surgical system. The da Vinci surgical system costs between \$1.0 and \$2.3 million, with an annual service agreement of \$100,000 to \$170,000. Instruments and accessories cost approximately \$1300 to \$2200 per surgical procedure.^[@B23]^ Although these costs are typically amortized over several years, this would still add significant additional costs to the robotic-assisted hysterectomy procedure and thus further increase the cost difference compared with an ES-assisted total laparoscopic hysterectomy procedure.

Strengths and Limitations
-------------------------

Strengths of our study include evaluation of a large database of patients and hospitals with a wide geographic representation of actual surgical costs throughout US hospitals. Additional strengths include the ability to compare cofounders including severity of illness, comorbid conditions, hospital teaching status, hospital region, and hospital bed size so that accurate cost comparisons are performed. Weaknesses of our study include dependence on billing data, which can have inherent inaccuracies, as well as having to infer the actual use of the ES during the total laparoscopic hysterectomy procedure. The indication for the total laparoscopic hysterectomy was also not available, which could potentially skew the type of hysterectomy performed toward robotic-assisted procedures for the more difficult cases. Information was also not available as to the surgeon\'s experience with the total laparoscopic hysterectomy procedure or the technique of laparoscopic suturing used in the NER group, which could impact surgical time. Another limitation of our study is the non-experimental study design. Although we have controlled for confounding variables, by using multivariate analysis, there still may exist variables that we were unable to control for.

CONCLUSION
==========

Our study is consistent with the limited cost data that are available in the medical literature on laparoscopic versus robotic-assisted hysterectomy procedures. In this study we found that the use of a disposable automated laparoscopic suturing device, the ES, is significantly more cost-effective than the use of the da Vinci surgical system for the performance of an inpatient total laparoscopic hysterectomy procedure for benign conditions. The ES also does not add cost compared with traditional total laparoscopic hysterectomy procedures because of the time savings that it enables in laparoscopic suturing. Therefore a disposable automated laparoscopic suturing device is an efficient and cost-effective method for laparoscopic suturing to close the vaginal cuff during a total laparoscopic hysterectomy procedure for benign conditions.
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